

## PRESS RELEASE

**Sosei Heptares notes abstracts and posters reporting clinical and preclinical data from studies with immuno-oncology candidate AZD4635, presented by AstraZeneca at AACR 2019, are available**

Tokyo, Japan and London, UK, 15 April 2019 – Sosei Group Corporation (“the Company”; TSE: 4565) notes that the abstracts presented by AstraZeneca at the 2019 American Association for Cancer Research (AACR) Annual Meeting (29 March to 3 April 2019) are available at the links below – the presented posters and a summary of key findings have now been added to the [Science Center](#) section on our website.

[Abstract #CT026](#): Merchant, MS, et al. Evidence of immune activation in the first-in-human Phase 1a dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors

[Abstract #LB-192](#): Barbon, CM, et al. The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells

– ENDS –

**About Sosei Heptares**

We are an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR<sup>®</sup> technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications. Its leading clinical programs include partnered candidates aimed at the symptomatic treatment of Alzheimer’s disease (with Allergan) and next generation immuno-oncology approaches to treat cancer (with AstraZeneca). Our additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Tokyo, Japan and houses its main R&D facility in Cambridge, UK.

“Sosei Heptares” is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit <https://www.soseiheptares.com/>

LinkedIn: [@soseiheptaresco](#) | Twitter: [@soseiheptaresco](#) | YouTube: [@soseiheptaresco](#)

A dark blue horizontal banner with a white circle on the left side, containing the text 'PRESS RELEASE' in white.

PRESS RELEASE

**Enquiries:**

**Sosei Heptares**

Investor Relations and Corporate Communications

Shinichiro Nishishita, Yu Okada

+81 (0)3 5210 3399

[IR@SoseiHeptares.com](mailto:IR@SoseiHeptares.com)

**Citigate Dewe Rogerson (for international media)**

Mark Swallow, David Dible

+44 (0)20 7638 9571

[SoseiHeptares@citigatedewerogerson.com](mailto:SoseiHeptares@citigatedewerogerson.com)

**Forward-looking statements**

This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Various risks may cause Sosei Group Corporation's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.